This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Incretin Effect in Patients With Chronic Pancreatitis

This study has been completed.
University of Copenhagen
Information provided by:
University Hospital, Gentofte, Copenhagen Identifier:
First received: March 12, 2008
Last updated: January 12, 2010
Last verified: March 2008
The phenomenon that oral glucose elicits a higher insulin response than does intravenous (iv) glucose, even at identical plasma glucose (PG) profiles (isoglycemia), is called the incretin effect. In type 2 diabetes mellitus (T2DM) the incretin effect has been shown to be markedly reduced or even abolished. It is not known whether the reduced incretin effect in T2DM is a primary event leading to T2DM or if it is merely a consequence of the diabetic state. To answer this question the investigators plan to estimate the incretin effect in 8 patients with secondary diabetes mellitus (DM) to chronic pancreatitis (CP) and compare it to the incretin effect of 8 patients with CP and normal glucose tolerance (NGT). Eight patients with T2DM and 8 healthy control subjects are studied for comparison. The incretin effect is measured by a 50-g oral glucose tolerance test and an isoglycemic intravenous glucose infusion.

Chronic Pancreatitis Type 2 Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Incretin Effect in Patients With Chronic Pancreatitis With and Without Secondary Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by University Hospital, Gentofte, Copenhagen:

Biospecimen Retention:   Samples With DNA
Blood samples

Enrollment: 32
Study Start Date: January 2006
Estimated Study Completion Date: July 2006

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with chronic pancreatitis with and without secondary diabetes mellitus

Inclusion Criteria:

  • Diagnosis of chronic pancreatitis with secondary diabetes mellitus
  • Diagnosis of chronic pancreatitis with normal glucose tolerance
  • Diagnosis of type 2 diabetes
  • Normal level of hemoglobin
  • Normal level of se-creatinine

Exclusion Criteria:

  • GAD-65 autoantibodies
  • ICA autoantibodies
  • Albuminuria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00638573

Gentofte University Hospital
Hellerup, Copenhagen County, Denmark, 2900
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
University of Copenhagen
Principal Investigator: Filip K Knop, MD University of Copenhagen
Study Director: Jens J Holst, MD DMSc University of Copenhagen
Study Director: Thure Krarup, MD DMSc Gentofte University Hospital
  More Information

Responsible Party: Filip K. Knop, Diabetes Research Division, Department of Internal Medicine F, Gentofte Hospital, University of Copenhagen Identifier: NCT00638573     History of Changes
Other Study ID Numbers: KA04034
Study First Received: March 12, 2008
Last Updated: January 12, 2010

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Pancreatitis, Chronic
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Pancreatic Diseases
Digestive System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on July 19, 2017